Press Releases

Affirm Holdings, Inc. (NASDAQ:AFRM) today announced it will participate in the following investor conferences: On September 8 and 9, 2026, Max Levchin (Founder and Chief Executive Officer), Rob O’Hare (Chief Financial Officer), and Zane Keller (Head of Investor Relations) will attend the Goldman Sachs Communacopia + Technology Conference in San Francisco, CA. On September 8, Mr. Levchin will participate in a fireside chat beginning at 3:05pm PT. The fireside chat will be webcast live on the Company’s investor relations website at https://investors.affirm.com/. A replay of the webcast will be available for a limited period of time following the conference. On September 15, 2026, Rob

REVTORPYK™ (gedatolisib) approved by the U.S. FDA for the treatment of HR+/HER2- PIK3CA Wild-Type locally advanced or metastatic breast cancer on July 14, 2026; on track for commercial launch late third quarter 2026NCCN® Clinical Practice Guidelines recommended REVTORPYK in combination with fulvestrant, with or without palbociclib, as a preferred Category 1 option for second-line therapy in HR+/HER2- advanced breast cancerThe Phase 3 PIK3CA mutant cohort of the VIKTORIA-1 trial achieved its primary endpoint by doubling the likelihood of survival without disease progression or death compared to alpelisib plus fulvestrant; a supplemental New Drug Application ("sNDA") is planned for submission

MIDLAND, Texas, Aug. 13, 2026 /PRNewswire/ -- Dawson Geophysical Company (NASDAQ:DWSN) (the "Company") today reported unaudited financial results for its second quarter ended June 30, 2026. Second quarter 2026 HighlightsRecognized fee revenue of $14 million, a 60% increase over the second quarter of 2025Net loss of $3.4 million, $0.11 per share, which included $1.7 million of strategic transaction costsGenerated Adjusted EBITDA of $0.6 million, an improvement of $1.8 million over the second quarter of 2025Fourth consecutive quarter of positive Adjusted EBITDA, for the first time since the three months ended September 30, 2018Year-to-Date 2026 HighlightsIncreased fee revenue 94% to $46.5 mill

SAN FRANCISCO, Aug. 13, 2026 /PRNewswire/ -- Docusign (NASDAQ:DOCU) today announced that it will release its second quarter fiscal 2027 financial results after the U.S. markets close on Thursday, September 3, 2026. The company will host a conference call and live webcast at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time) on the same day to discuss its financial performance and business outlook. Conference Call DetailsLive Webcast: Webcast Link Domestic Toll-Free Dial-In: (877) 407-0784International Dial-In: (201) 689-8560An archived replay of the webcast will be available the following day on Docusign's Investor Relations websi

GOOSE CREEK, S.C., Aug. 13, 2026 /PRNewswire/ -- HireQuest, Inc. (NASDAQ:HQI), a national franchisor of on-demand staffing and executive search services, today announced that its Board of Directors has declared a quarterly dividend of $0.06 per share. The dividend is payable September 15, 2026, to shareholders of record at the close of business on September 1, 2026. About HireQuest HireQuest is a franchisor of staffing solutions with a footprint across the U.S. and international markets. Through its primary divisions - HireQuest Direct, HireQuest Health, Snelling, TradeCorp and DriverQuest - the company delivers temporary, dire

Pinterest, Inc. (NYSE:PINS) announced today that Bill Ready, CEO, will participate in the Goldman Sachs Communacopia + Technology Conference. The session is scheduled for September 9, 2026 at 8:10 a.m PT / 11:10 a.m. ET. A live webcast and replay of the presentation will be publicly available on Pinterest’s Investor Relations website at investor.pinterest.com. Disclosure Information Pinterest uses and intends to continue to use its Investor Relations website as a means of disclosing material nonpublic information and for complying with its disclosure obligations under Regulation FD. Accordingly, investors should monitor the company’s Investor Relations website, in addition to followin

ROCHESTER, N.Y., Aug. 13, 2026 /PRNewswire/ -- Vuzix® Corporation (NASDAQ:VUZI), ("Vuzix" or, the "Company"), a leading supplier of AI-powered smart glasses, waveguides and Augmented Reality (AR) technologies, today reported its second quarter results for the three months ended June 30, 2026. "Our branded enterprise smart glasses business continues to generate revenue, customer insight and market credibility, while opening new doors for Vuzix in the smart glasses ecosystem as an OEM smart glasses, waveguides and display systems provider," said Paul Travers, President and Chief Executive Officer of Vuzix. "We delivered our initi

SHANGHAI, Aug. 13, 2026 /PRNewswire/ -- Boqii Holding Limited ("Boqii" or the "Company") (NYSE:BQ), a leading pet-focused platform in China, announced today that the Company had become aware of unusual trading activity in its Class A ordinary shares on the NYSE American LLC (the "NYSE American") on August 12, 2026. The Company is issuing this press release pursuant to Section 401(d) of the NYSE American Company Guide. Following appropriate internal review and consultation, the Company confirms that it is not aware of any material developments in its business or affairs beyond those previously disclosed publicly.  Investors should rely solely on the Company's official filings and press releas

SAN DIEGO, Aug. 13, 2026 /PRNewswire/ -- Inhibrx Biosciences, Inc. (NASDAQ:INBX) ("Inhibrx" or the "Company") today reported financial results for the second quarter of 2026. The biopharmaceutical company has two programs in ongoing clinical trials. Recent Corporate Highlights and Upcoming MilestonesOxford Loan Amendment. In July 2026, the Company entered into a second amendment to the Loan and Security Agreement (Second Amendment) with Oxford Finance LLC (Oxford), which provides for an additional $325.0 million in gross proceeds, (i) $100.0 million of which was funded upon execution of the amendment and (ii) up to an additiona

Houston, Texas--(Newsfile Corp. - August 13, 2026) - MultiSensor AI Holdings, Inc. (NASDAQ:MSAI) (the "Company", "MultiSensor AI" or "MSAI") today announced financial results for the second quarter ended June 30, 2026.Asim Akram, Chief Executive Officer, said, "Industrial customers are moving from reactive maintenance to data-driven operations. They need one platform that combines multiple sensor technologies into actionable intelligence before failures occur. During the quarter, we expanded MSAI Connect with wireless vibration monitoring, giving customers thermal and vibration intelligence in a single workflow and taking another step toward becoming the operating system for industrial asset

The acquisition of Moltex brings over a decade of advanced nuclear R&D, backed by more than C$96 million in private investment and public funding from Canada and the U.S. Department of Energy.Asset-led transaction to add intellectual property and development materials related principally to the SSR-W advanced reactor and WATSS spent nuclear fuel recycling technologies.Mississauga, Ontario--(Newsfile Corp. - August 13, 2026) - Nuclea Energy Inc. ("Nuclea" or the "Company"), an advanced nuclear technology company headquartered in Mississauga, Ontario, developing the Morpheus microreactor, a lead-cooled, factory-built micro-modular reactor, today announces that its wholly owned subsidiary, Nucl

Toronto, Ontario--(Newsfile Corp. - August 13, 2026) - Akanda Corp. (NASDAQ:AKAN) ("Akanda") and its 100% owned subsidiary First Towers & Fiber Corp. ("FTF" or the "Company"), an emerging telecommunications infrastructure developer in Mexico, today announced an update on recent operational milestones and expansion progress, underscoring its continued growth in telecommunications infrastructure.Core Business and Tower OperationsFTF maintains a portfolio of 28 cellular tower sites, all fully operational and actively radiating signal. The Company continues to focus on its passive infrastructure model, leasing tower assets to a growing roster of network providers.Fiber Network Deployment and Rev

– Q2 Total Revenue of $24.3 million, up 20% from Q1 2026 and 5% from Q2 2025 – – Annual Recurring Revenue (ARR) of $62.0 million, up modestly year over year – – Completed first phase of restructuring, delivering $11.3 million in annualized cost reductions, or approximately 11% of annual Operating Expenses as compared to the trailing 12 months ended June 30, 2026 – – Targeting additional cost reductions of $3.5 million to $8.5 million by year-end 2026, representing total annualized Operating Expense reductions of approximately 15% to 20%, with further reductions planned for 2027 – Veritone, Inc. (NASDAQ:VERI) ("Veritone" or the "Company"), a leader in building enterprise AI solutions

WILMINGTON, N.C., Aug. 13, 2026 (GLOBE NEWSWIRE) -- nCino, Inc. (NASDAQ:NCNO), the platform for agentic AI banking, will report financial results for its second quarter ended July 31, 2026, after the market close on Tuesday, August 25, 2026. nCino will host a conference call and webcast that day at 4:30 p.m. ET to discuss its financial results. Event: nCino’s Second Quarter Fiscal Year 2027 Financial Results Conference CallDate and Time: Tuesday, August 25, 2026 at 4:30 p.m. ETWebcast Link: https://investor.ncino.com/Replay: A webcast replay will be available on nCino’s Investor Relations website following the call. About nCinonCino (NASDAQ:NCNO) is the platform for agentic AI banking. W

Revenue reached $5.1 million; Gross margin improved to 90% from 80% in the prior year  Broad Vision AI platform traction drove strong growth in ROC SDK, ROC ABIS, and ROC Enroll ROC Evidence achieves milestone upon 2Q26 commercialization, generated first revenue ahead of plan DENVER, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Rank One Computing Corporation d/b/a ROC, (NASDAQ:ROC) ("ROC" or the "Company"), a U.S. leader in Vision AI, building unified biometric, video analytics, and decision intelligence solutions, today announces financial results for the second quarter ended June 30, 2026. "In 2Q, ROC's revenue nearly doubled sequentially to $5.1 million, gross margin expanded to 90%, and gove

RADNOR, Pa., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ:MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and aldosterone-related adverse outcomes in comorbid conditions such as chronic kidney disease, obstructive sleep apnea and other diseases driven by dysregulated aldosterone, announced today that, on August 10, 2026, a majority of the independent directors of Mineralys’ Board of Directors granted an inducement stock option award covering 135,000 shares and an inducement restricted stock unit award covering 102,400 shares of Mineralys common stock to Dr. Terry Ferguson, Mineralys’ newly appointed Chief Medical Officer.

$10 million funded at closing; second $5 million tranche unlocked upon FDA 510(k) clearance of NXT-41xPreserves shareholder value by funding commercialization of Elutia's next-generation antibiotic-eluting biomatrix without an equity offeringNXT-41x targets the 15–20% post-operative infection rates in multiple complex plastic and reconstructive surgical procedures GAITHERSBURG, Md., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Elutia Inc. (NASDAQ:ELUT) ("Elutia" or the "Company"), a pioneer in drug-eluting biomatrix technologies, today announced a $15 million growth capital financing agreement with Avenue Capital Group ("Avenue Capital"). The transaction strengthens Elutia’s balance sheet and funds

ATHENS, Greece, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Dynagas LNG Partners LP (the "Partnership") (NYSE: "DLNG"), an owner of LNG carriers, today announced that its Board of Directors has declared a quarterly cash distribution with respect to the quarter ended June 30, 2026 of $0.050 per common unit. The cash distribution is payable on August 28, 2026 to all common unit holders of record as of August 24, 2026. About Dynagas LNG Partners LP Dynagas LNG Partners LP (NYSE:DLNG) is a master limited partnership which owns LNG carriers employed on multi-year charters. The Partnership’s current fleet consists of six LNG carriers, with aggregate carrying capacity of approximately 914,000 cubic meter

Secured regulatory clearance in two jurisdictions to initiate first-in-human Phase 1/2 clinical trial of CMP-002 in patients with SYNGAP-1 related disorder; trial initiation anticipated in the fourth quarter of this year. Received $50.1 million from fully subscribed second closing of private placement initially announced September 2025. Cash runway extended through the end of 2028. WATERTOWN, Mass., Aug. 13, 2026 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation ("CAMP4") (NASDAQ:CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting therapeutics designed to upregulate gene expression with the goal of restoring healthy protein levels to treat

Successful End-of-Phase 2 meeting with FDA supports advancement of tegoprubart into a global Phase 3 kidney transplantation trial, on track to initiate in late 2026 Long-term Phase 2 BESTOW data presented at ATC 2026 demonstrated sustained higher kidney function and improved patient-reported outcomes with tegoprubart compared with tacrolimus Updated islet cell transplantation data presented at ADA 2026 showed 100% insulin independence in all 12 patients with type 1 diabetes Cash, cash equivalents and short-term investments of $88.8 million as of June 30, 2026 IRVINE, Calif., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. ("Eledon") (NASDAQ:ELDN) today reported its seco